top of page
Decoding Neurological Disease. Building Medicines.
CELLTIUM is developing precision therapies for CMT1A and related neurological disorders. By combining deep disease biology with the proprietary PRECISION™ platform, we are advancing a translationally driven approach to drug discovery.
A New Model for Neurotherapeutics
Through the PRECISION™ platform, we integrate disease biology, quantitative phenotyping, and AI into a single translational framework — from target identification to lead optimization — to build first‑in‑class therapies for underserved neurological disorders.
Targeting the Core Biology
We are advancing a portfolio of mechanistically distinct small-molecule therapies for CMT1A and related neuropathies, designed to address underlying disease biology, restore peripheral nerve function, and deliver first-in-class disease-modifying potential.
Partner With Us
We welcome strategic collaborations with pharmaceutical companies and investors across co-development, licensing, and strategic investment — to advance our CMT1A programs and further develop the PRECISION™ platform.
bottom of page